BFM
ZYNE

Boothbay Fund Management’s Zynerba Pharmaceuticals, Inc ZYNE Stock Holding History

Boothbay Fund Management’s Portfolio ZYNE Stock Details ZYNE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q3 		– Sell
-81,667
Closed -$275K – 1291
2020
Q2 		$275K Buy
+81,667
New +$386K 0.02% 719

Other funds holding ZYNE

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
EMG
ETF Managers Group Summit, New Jersey $3.1B AUM 17.12% 1-Year Est. Return
Mirae Asset Global Investments
Mirae Asset Global Investments Seoul, South Korea $67.7B AUM 51.91% 1-Year Est. Return
PCM
Prentice Capital Management Greenwich, Connecticut $45.7M AUM 2.65% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
BCM
Bridgeway Capital Management Houston, Texas $4.97B AUM 44.96% 1-Year Est. Return

Boothbay Fund Management's ZYNE Position: Q3 2020 in Review

Boothbay Fund Management sold out of Zynerba Pharmaceuticals, Inc (ZYNE) in Q3 2020, closing a stake of 81,667 shares — an estimated $275K sold.

Boothbay Fund Management first reported a position in ZYNE in Q2 2020 and held it in 1 quarter. The position peaked at $275K in Q2 2020. 66 funds tracked by Wall St. Rank hold ZYNE as of Q3 2020.

  • Boothbay Fund Management reported no remaining Zynerba Pharmaceuticals, Inc position as of Q3 2020 after selling out during the quarter.
  • Boothbay Fund Management sold 81,667 Zynerba Pharmaceuticals, Inc shares in Q3 2020, an estimated $275K.
  • Boothbay Fund Management first reported a position in Zynerba Pharmaceuticals, Inc in Q2 2020 and held it in 1 quarter.
  • Boothbay Fund Management's Zynerba Pharmaceuticals, Inc position peaked at $275K in Q2 2020.
  • 66 funds tracked by Wall St. Rank held Zynerba Pharmaceuticals, Inc as of Q3 2020.

Based on Boothbay Fund Management's 13F filing for Q3 2020, filed 16 Nov 2020.